Icahn ups stake in Enzon, wants company to consider sale

By Lisa Kerner

Charlotte, N.C., March 14 - Enzon Pharmaceuticals, Inc. investors led by Carl C. Icahn and High River LP bought 872,103 shares of Enzon common stock.

According to a schedule 13D filing with the Securities and Exchange Commission, the shares were acquired between March 4 and March 12 priced from $8.27 to $8.82.

The investors have urged Enzon management to conduct a comprehensive review of strategic alternatives, including a spinoff, monetization of certain assets or a sale of the company.

Icahn and his affiliates beneficially own 3,072,103 shares, or 6.93%, of the Bridgewater, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.